Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23412821 | 0.77 | ELANE (0.36) | ELANE | |
| SCHEMBL6383414 | 0.77 | POLB (0.36) | ELANEHTR4KCNH2POLB | |
| SCHEMBL2207892 | 0.76 | HSD17B10 (0.39) | ELANE | |
| SCHEMBL1523092 | 0.74 | ALDH1A1 (0.42) | ELANECYP1A2CYP2C19 | |
| SCHEMBL5616743 | 0.73 | ELANE (0.34) | ELANE | |
| SCHEMBL2206340 | 0.73 | ELANE (0.40) | ELANEKMT2A | |
| SCHEMBL2207598 | 0.71 | ELANE (0.38) | ELANEMEN1POLBKMT2A | |
| SCHEMBL6674168 | 0.70 | PARP15 (0.41) | HTR4KCNH2MEN1POLBCYP3A4 | |
| SCHEMBL6636939 | 0.70 | HTR4 (0.39) | HTR4KCNH2CYP1A2CYP2C19 | |
| SCHEMBL8745086 | 0.69 | POLB (0.47) | ELANEMEN1CYP1A2POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982040-B2 | Thienopyridinone compounds and methods of treatment | NANOTHERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7576211-B2 | Synthesis of thienopyridinone compounds and related intermediates | EPIX DELAWARE, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090163537-A1 | Thienopyridinone Compounds and Methods of Treatment | NANOSHIFT, LLC | 2009-06-25 | — | — | US | disclosed |
| US-7488736-B2 | Thienopyridinone compounds and methods of treatment | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20060084805-A1 | Synthesis of thienopyridinone compounds and related intermediates | NANOSHIFT, LLC | 2006-04-20 | — | — | US | disclosed |
| US-20050256153-A1 | Thienopyridinone compounds and methods of treatment | NANOSHIFT, LLC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163537-A1 | Thienopyridinone Compounds and Methods of Treatment | HTR5A, GIPR, TBXA2R | ELANE 1738/4885HTR4 22/4885KCNH2 824/4885 |
| US-20060084805-A1 | Synthesis of thienopyridinone compounds and related intermediates | HTR5A, GIPR, HTR1A | ELANE 2186/4885HTR4 34/4885KCNH2 1035/4885 |
| US-20050256153-A1 | Thienopyridinone compounds and methods of treatment | HTR5A, GIPR, TBXA2R | ELANE 1738/4885HTR4 22/4885KCNH2 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.